Previous close | 265.70 |
Open | 266.70 |
Bid | 268.60 x N/A |
Ask | 269.50 x N/A |
Day's range | 266.70 - 267.80 |
52-week range | 190.85 - 267.80 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., June 05, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, Florida.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., May 01, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-over-year to $677.7 million, compared to $506.9 million in the first quarter of 2023.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 26, 2024--Please replace the photo for release dated April 24, 2024 with the accompanying corrected photo.